Fax: (011) 39
Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma
A Phase I study
Article first published online: 23 FEB 2001
Copyright © 2001 American Cancer Society
Volume 91, Issue 4, pages 712–720, 15 February 2001
How to Cite
Garufi, C., Dogliotti, L., D'Attino, R. M., Tampellini, M., Aschelter, A. M., Pugliese, P., Perrone, M., Nisticó, C., Comis, S. and Terzoli, E. (2001), Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma. Cancer, 91: 712–720. doi: 10.1002/1097-0142(20010215)91:4<712::AID-CNCR1056>3.0.CO;2-4
- Issue published online: 23 FEB 2001
- Article first published online: 23 FEB 2001
- Manuscript Accepted: 3 NOV 2000
- Manuscript Revised: 18 OCT 2000
- Manuscript Received: 21 JUN 2000
- Rhône-Poulenc Rorer, Origgio (VA), Italy
- Associazione Italiana Ricerca Sul Cancro (AIRC)
- colorectal carcinoma;
- Phase I study
Irinotecan (CPT-11) is an active drug in the treatment of patients with advanced colorectal carcinoma. The infusion of 5-fluorouracil (5-FU) according to circadian rhythms was used previously to decrease toxicity and to increase its therapeutic efficacy. The objective of this study was to establish the maximum tolerated dose (MTD) of CPT-11 together with a chronomodulated infusion of 5-FU and the l-form of folinic acid (FA). Secondary end points were the assessment of activity and quality of life (QoL).
Twenty-six patients with advanced colorectal carcinoma who had received previous treatment with 5-FU were entered on this Phase I study. At least three patients were recruited at each dose level. The CPT-11 starting dose was 175 mg/m2 on Day 1 with an increase of 50 mg/m2 per dose level. A daily administration of chronomodulated 5-FU (900 mg/m2; peak delivery rate at 04:00) and FA (175 mg/m2; peak delivery rate at 04:00) for 5 days every 3 weeks was given with CPT-11. After the first three patients, the 5-FU dose was reduced to 700 mg/m2 per day due to toxicity. No intrapatient dose escalation was allowed.
One hundred sixty-one courses were delivered. Dose-limiting toxicity was observed during the first course in seven patients (27%). Four patients developed neutropenia, with one patient reporting febrile neutropenia, two patients reporting severe stomatitis, and six patients reporting severe diarrhea. CPT-11 MTD was reached at 350 mg/m2 when a toxic death was observed with a recommended dose of 325 mg/m2. Six partial responses were observed (23%). The median duration of response and the progression free and overall survival rates were 199 days, 175 days, and 359 days, respectively. QoL was not affected by the treatment.
The recommended dose for Phase II trials is 325 mg/m2 CPT-11 on Day 1, which is similar to the dose given as a single agent, together with a 5-day chronomodulated infusion of 700 mg/m2 5-FU and 175 mg/m2 FA. Intensification of this schedule every 2 weeks should be achievable. Cancer 2001;91:712–20. © 2001 American Cancer Society.